Search

Your search keyword '"Giulia Gamboni"' showing total 5 results
Start Over Author "Giulia Gamboni"
5 results on '"Giulia Gamboni"'

1. Bloodstream Infections Due to Wild-Type Pseudomonas aeruginosa: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes

Author

Carlo Pallotto, Andrea Tommasi, Elisabetta Svizzeretto, Giovanni Genga, Giulia Gamboni, Anna Gidari, and Daniela Francisci

Subjects
Pseudomonas aeruginosa, bloodstream infections, BSI, carbapenem sparing, antimicrobial stewardship, Other systems of medicine, RZ201-999
Abstract

Background. Pseudomonas aeruginosa is one of the major concerns among bacterial diseases even when it shows a wild-type susceptibility pattern. In 2020, EUCAST reconsidered antibiogram interpretation shifting “I” from “intermediate” to “sensible, increased exposure” with possible significant impact on antibiotic prescription. The aim of this study was to evaluate mortality in patients with P. aeruginosa bloodstream infections treated with antipseudomonal penicillins or cephalosporins vs. carbapenems and ceftazidime/avibactam. Methods. This is a retrospective observational study. All the patients with a bloodstream infection due to P. aeruginosa admitted to our hospital were enrolled. Exclusion criteria were as follows: extremely critical conditions, age p > 0.1). In group A, in-hospital BSI-related mortality was 23.2% (13/56), while it was 14.3% (3/21) in group B (p > 0.1). After multivariate analysis, only the PITT score represented a risk factor for BSI-related mortality (OR 2.917, 95% CI 1.381–6.163). Conclusions. Both all-cause and BSI-related mortality were comparable between the two groups. Treatment with carbapenem or ceftazidime/avibactam did not represent a protective factor for mortality in wild-type P. aeruginosa BSI.

Published
2024
Full Text
View/download PDF

2. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

Author

Paolo Maggi, Giuseppe Vittorio De Socio, Barbara Menzaghi, Chiara Molteni, Nicola Squillace, Lucia Taramasso, Marta Guastavigna, Giulia Gamboni, Giordano Madeddu, Francesca Vichi, Antonio Cascio, Eleonora Sarchi, Giovanni Pellicanò, Canio Vito Martinelli, Benedetto Maurizio Celesia, Laura Valsecchi, Roberto Gulminetti, Giovanni Cenderello, Andrea Parisini, Leonardo Calza, Katia Falasca, Giancarlo Orofino, Elena Ricci, Antonio Di Biagio, and Paolo Bonfanti

Subjects
HIV, Multimorbidity, ART exposure, Age, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background In persons living with HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging associated with chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART). Methods To explore the association of chronological age, age at first ART, and exposure to ART with non-communicable chronic diseases, we performed a cross-sectional analysis to evaluate the prevalence of comorbidities in patients enrolled in the SCOLTA Project, stratified by groups of chronological age (50–59 and 60–69 years) and by years of antiretroviral treatment (ART, ≤ 3 or > 3 years). Results In 1394 subjects (23.8% women), mean age at enrollment was 57.4 (SD 6.5) years, and at first ART 45.3 (SD 10.7). Men were older than women both at enrollment (57.6 vs 56.8, p = 0.06) and at first ART (45.8 vs 43.6, p = 0.0009). ART duration was longer in women (13.1 vs 11.7 years, p = 0.01). The age- and sex-adjusted rate ratios (aRRs, and 95% confidence interval, CI) showed that longer ART exposure was associated with dyslipidemia (aRR 1.35, 95% CI 1.20–1.52), hypertension (aRR 1.52, 95% CI 1.22–1.89), liver disease (aRR 1.78, 95% CI 1.32–2.41), osteopenia/osteoporosis (aRR 2.88, 95% CI 1.65–5.03) and multimorbidity (aRR 1.36, 95% CI 1.21–1.54). These findings were confirmed in strata of age, adjusting for sex. Conclusions Our data suggest that longer ART exposure was associated with increased risk of dyslipidemia, hypertension, and osteopenia/osteoporosis, hence the presence of multimorbidity, possibly due to the exposition to more toxic antiretrovirals. We observed different comorbidities, according to ART exposure and age.

Published
2022
Full Text
View/download PDF

3. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?

Author

Zollo, V, Menzaghi, B, Molteni, C, Squillace, N, Taramasso, L, De Luca, I, Gamboni, G, Altobelli, D, Guastavigna, M, Madeddu, G, Vichi9 Antonio Cascio, F, Sarchi, E, Pellicanò, G, Martinelli, C, Maurizio Celesia, B, Valsecchi, L, Gulminetti, R, Cenderello, G, Parisini, A, Calza, L, Falasca, K, Di Biagio, A, Bonfanti, P, Orofino, G, Maggi., P, Verdiana Zollo, Barbara Menzaghi, Chiara Molteni, Nicola Squillace, Lucia Taramasso, Ilaria De Luca, Giulia Gamboni, Debora Altobelli, Marta Guastavigna, Giordano Madeddu, Francesca Vichi9 Antonio Cascio, Eleonora Sarchi, Giovanni Pellicanò, Canio Martinelli, Benedetto Maurizio Celesia, Laura Valsecchi, Roberto Gulminetti, Giovanni Cenderello, Andrea Parisini, Leonardo Calza, Katia Falasca, Antonio Di Biagio, Paolo Bonfanti, Giancarlo Orofino, Paolo Maggi., Zollo, V, Menzaghi, B, Molteni, C, Squillace, N, Taramasso, L, De Luca, I, Gamboni, G, Altobelli, D, Guastavigna, M, Madeddu, G, Vichi9 Antonio Cascio, F, Sarchi, E, Pellicanò, G, Martinelli, C, Maurizio Celesia, B, Valsecchi, L, Gulminetti, R, Cenderello, G, Parisini, A, Calza, L, Falasca, K, Di Biagio, A, Bonfanti, P, Orofino, G, Maggi., P, Verdiana Zollo, Barbara Menzaghi, Chiara Molteni, Nicola Squillace, Lucia Taramasso, Ilaria De Luca, Giulia Gamboni, Debora Altobelli, Marta Guastavigna, Giordano Madeddu, Francesca Vichi9 Antonio Cascio, Eleonora Sarchi, Giovanni Pellicanò, Canio Martinelli, Benedetto Maurizio Celesia, Laura Valsecchi, Roberto Gulminetti, Giovanni Cenderello, Andrea Parisini, Leonardo Calza, Katia Falasca, Antonio Di Biagio, Paolo Bonfanti, Giancarlo Orofino, and Paolo Maggi.

Abstract

In Persons Living With HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging linked to prolonged survival, chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART). Chronological age, age at HIV diagnosis, and exposure to ART may exert an effect on qualitative and quantitative differences. To explore this hypothesis, we evaluated the prevalence of some selected comorbidities in patients enrolled in the SCOLTA Project, by groups of chronological age (50- 59 and ≥60 years old) and ART duration. In 1336 subjects (23.9% women), ART duration was similar between age groups, both when considered in continuous (p=0.85) and in categories (p=0.88). As expected, comorbidities and multimorbidity were less frequent in the 50-59 than in the ≥60 years class. The age- and sex-adjusted odds ratios (ORs) showed that, in the 50-59 years group, a consistent and significant risk increase was observed through ART duration categories for CVD (ORs from 1.68 to 2.18), dyslipidemia (ORs from 3.61 to 9.08) and osteopenia/osteoporosis (ORs from 3.74 to 6.23). Consequently, the risk of multimorbidity also increased across ART duration categories (ORs from 2.04 to 4.40). In the ≥60 years group, the CVD risk was significantly increased only in those patients with ART duration ≥20 years (OR 2.61, 95% CI 1.22-5.58, reference category ≤6 months). Dyslipidemia and multimorbidity increase were consistently associated with longer ART duration. In conclusion, age, age at HIV infection diagnosis, and ART exposure were associated to multimorbidity in PLWH.&nbsp

Published
2022

4. BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV

Author

Anna Gidari, Sabrina Bastianelli, Sara Pierucci, Chiara Busti, Samuele Sabbatini, Elisabetta Schiaroli, Sara Benedetti, Giulia Gamboni, Alessandra Lanzi, and Daniela Francisci

Subjects
PLWH, SARS-CoV-2, HIV, COVID-19, Viral Vaccines, HIV Infections, Antibodies, Viral, Antibodies, Neutralizing, Antibodies, neutralizing, Infectious Diseases, vaccine, Virology, Humans, Viral, BNT162 Vaccine
Abstract

Background: Vaccines have had a fundamental impact in containing the ongoing Coronavirus Disease 2019 (COVID-19) pandemic. However, there are few efficacy data relating to frail patients, including the HIV-positive patient. Objective: This study evaluated the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) serum neutralization in People Living with HIV (PLWH) compared to a cohort of healthy volunteers both vaccinated with BNT162b2. Methods: A serum sample was then withdrawn 14-21 days after the second dose of the vaccine and a serum neutralization assay was performed on Vero-E6 cells. The experiments were performed using two strains of SARS-CoV-2 as 20A.EU1 and B.1.617.2. Results: PLWH on Antiretroviral Therapy (ART) showed a vaccine response comparable to the healthy subjects. No correlation between CD4 count or CD4/CD8 and neutralizing antibodies (NT-Abs) has been found. No differences in NT-Abs between patients with CD4 nadir above or under 200 cells/µl have been found. In both cohorts, vaccine-elicited serum better neutralized 20A.EU1 than B.1.617.2 strain. Conclusion: PLWH in ART and with good immuno-virological recovery showed a vaccine response comparable to that of healthy subjects and regardless of their immunological status at HIV infection diagnosis. However, larger studies are needed to confirm our results and to evaluate the vaccine response even in patients with low CD4 counts.

Published
2022

5. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?

Author

Verdiana Zollo, Barbara Menzaghi, Chiara Molteni, Nicola Squillace, Lucia Taramasso, Ilaria De Luca, Giulia Gamboni, Debora Altobelli, Marta Guastavigna, Giordano Madeddu, Francesca Vichi9 Antonio Cascio, Eleonora Sarchi, Giovanni Pellicanò, Canio Martinelli, Benedetto Maurizio Celesia, Laura Valsecchi, Roberto Gulminetti, Giovanni Cenderello, Andrea Parisini, Leonardo Calza, Katia Falasca, Antonio Di Biagio, Paolo Bonfanti, Giancarlo Orofino, Paolo Maggi., Zollo, V, Menzaghi, B, Molteni, C, Squillace, N, Taramasso, L, De Luca, I, Gamboni, G, Altobelli, D, Guastavigna, M, Madeddu, G, Vichi9 Antonio Cascio, F, Sarchi, E, Pellicanò, G, Martinelli, C, Maurizio Celesia, B, Valsecchi, L, Gulminetti, R, Cenderello, G, Parisini, A, Calza, L, Falasca, K, Di Biagio, A, Bonfanti, P, Orofino, G, and Maggi., P

Subjects
ART duration, multimorbidity, age, HIV
Abstract

Nelle persone che vivono con HIV (PLWH), il peso delle patologie corniche non trasmissibili è aumentato nel tempo, a causa dell’invecchiamento legato a una maggiore sopravvivenza, all’infiammazione cronica, all’attivazione del sistema immunitario, e all’esposizione a lungo termine alla terapia antiretrovirale (ART). L’età anagrafica, quella alla diagnosi di infezione da HIV, e l’esposizione alla ART sono fattori che possono esercitare un effetto sulle differenze sia qualitative che quantitative tra le comorbidità.Per esplorare questa ipotesi, abbiamo valutato la prevalenza di alcune patologie selezionate nei pazienti arruolati nel progetto SCOLTA, per gruppi di età (50-59 e ≥60 anni) e durata della ART. In 1336 soggetti (23.9% donne), la durata della ART era simile tra gruppi di età, sia considerata in continuo (p=0.85) che in categorie (p=0.88). Come atteso, le comorbidità e la multimorbidità erano meno frequenti nel gruppo 50-59 che in quello ≥60 anni. Gli odds ratios (ORs) aggiustati per sesso ed età hanno mostrato che, nella categoria 50-59, si rilevava un aumento di rischio significativo e coerente in categorie di durata della ART, per le malattie cardiovascolari (CVD) (ORs da 1.68 a 2.18), dislipidemia (ORs da 3.61 a 9.08) e osteopenia/osteoporosi (ORs da 3.74 a 6.23). Di conseguenza, anche il rischio di multimorbidità aumentava attraverso le classi di durata della ART (ORs da 2.04 a 4.40). Nel gruppo ≥60 anni, il rischio CVD era significativamente più elevato solo nei pazienti con durata della ART ≥20 anni (OR 2.61, 95% intervallo di confidenza al 95% 1.22-5.58, categoria di riferimento ≤6 mesi). L’aumento di dislipidemia e multimorbidità era coerentemente associato con una maggiore durata della ART.In conclusione, l’età anagrafica, quella alla diagnosi di infezione da HIV, e l’esposizione alla ART sono associate alla multi-morbidità nelle PLWH.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results